HomeClinical TopicsFDA approves Tanzeum to treat type 2 diabetes

FDA approves Tanzeum to treat type 2 diabetes

On April 3, the U.S. Food and Drug Administration (FDA) approved Tanzeum (albiglutide) subcutaneous injection to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.
Read more.

1 COMMENT

  1. The purpose of the FDA is to protect and promote the health of the public. However, studies show that the FDA approves many products that are causing tremendous harm to the public’s health. In order for the FDA to function properly and safeguard consumers, it needs to be free from unwarranted pharmaceutical industry and corporation influences. Lack of transparency, corruption, and bias prevents the FDA from carrying out its functions.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

Pregnant woman drinking coffee

Cup of Coffee Can Lessen Gestational Diabetes Risk

Pregnant mothers concerned about being able to safely enjoy their morning cup of coffee should be reassured by a recent University of Pennsylvania study...